OKYO Pharma Announces Positive Phase 2 Data for Urcosimod
Ticker: OKYO · Form: 6-K · Filed: Jul 16, 2025 · CIK: 1849296
Sentiment: bullish
Topics: clinical-trial-results, biotech, drug-development, ophthalmology
TL;DR
OKYO Pharma's NCP drug urcosimod shows positive Phase 2 results, first of its kind study.
AI Summary
On July 16, 2025, OKYO Pharma Ltd announced positive top-line data from its 18-patient Phase 2 trial for urcosimod (formerly OK-101) to treat Neuropathic Corneal Pain (NCP). This marks the first clinical study conducted by any company specifically targeting NCP disease, addressing a significant unmet medical need.
Why It Matters
This positive data could pave the way for a new treatment for Neuropathic Corneal Pain, a condition with limited therapeutic options.
Risk Assessment
Risk Level: medium — While the data is positive, it's from a small Phase 2 trial, and further development and regulatory approval are still required.
Key Numbers
- 18-patient — Phase 2 Trial Size (Indicates the scale of the study that yielded positive results.)
Key Players & Entities
- OKYO Pharma Ltd (company) — Registrant
- urcosimod (drug) — Investigational drug
- OK-101 (drug) — Former name of urcosimod
- Neuropathic Corneal Pain (NCP) (disease) — Condition being treated
- July 16, 2025 (date) — Date of announcement
- 18-patient (trial_size) — Size of Phase 2 trial
FAQ
What is the primary indication for urcosimod?
Urcosimod (formerly OK-101) is being investigated for the treatment of Neuropathic Corneal Pain (NCP).
What stage of clinical trial has urcosimod completed?
OKYO Pharma Ltd announced positive top-line data from a recently closed 18-patient Phase 2 trial of urcosimod.
When was this data announced?
The announcement was made on July 16, 2025.
What is unique about this clinical study?
This is the first clinical study conducted by any company to treat Neuropathic Corneal Pain (NCP) disease.
What is the former name of urcosimod?
The former name of urcosimod was OK-101.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 16, 2025 regarding OKYO Pharma Ltd (OKYO).